LJI308
CAS No. : 1627709-94-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $140 | In-stock |
| 10mg | $240 | In-stock |
| 25mg | $520 | In-stock |
| 50mg | $884 | In-stock |
| 100mg | $1500 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-19713 |
| M.Wt: | 368.38 |
| Formula: | C21H18F2N2O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 25 mg/mL (ultrasonic) |
LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC50s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation[1][2].
In Vitro: LJI308 inhibits S6K1 with an IC50 of 0.8 μM[1].
LJI308 inhibits YB-1 phosphorylation in CRC cells at concentrations of 5 to 25 μM. In a dose kinetics experiment, LJI308, starting at 2.5 μM, inhibits YB-1 phosphorylation in the KRAS mutated TNBC cell line MDA-MB-231 by approximately 86%. LJI308 effectively blocks RSK and YB-1 phosphorylation after EGF stimulation and after irradiation in KRAS wild-type HBL-100 cells[2].
LJI308 (1-10 μM; 96 hours) decreases cell viability by up to 90%[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- LJI308
- Cat. No.:
- HY-19713
- Quantity:
Your information is safe with us.